147460-41-1

Basic information

• Product Name: 2-Bromo-5-fluorophenol
• Synonyms: 2-BROMO-5-FLUOROPHENOL;2-Brome-5-Fluorophenol;Phenol, 2-bromo-5-fluoro-;2-Bromo-5-fluorophenol 98%;2-Bromo-5-fluorophenol98%;2-BROMO-5-FLUOROPHENOL 0.99 COLORLESS TRANSPARENT LIQUID;2-Bromo-5-fluorophenol,97%;2-Bromo-5-fluorophenol,99%
• CAS NO: 147460-41-1
• Molecular Formula: C₆H₄BrFO
• Molecular Weight: 191
• EINECS: -0
• Product Categories: Aromatic Phenols;Fluorobenzene;Phenol&Thiophenol&Mercaptan;Bromine Compounds;Fluorine Compounds;Phenols;Organic Building Blocks;Oxygen Compounds
• Mol File: 147460-41-1.mol
• Article Data: 2

Chemical Properties

• Melting Point: 185°C
• Boiling Point: 185°C
• Flash Point: 189 °F
• Appearance: Clear colorless to light yellow/Liquid
• Density: 1.717 g/mL at 25 °C(lit.)
• Vapor Pressure: 0.0222mmHg at 25°C
• Refractive Index: n20/D 1.553(lit.)
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• PKA: 7.43±0.10(Predicted)
• BRN: 7915214
• CAS DataBase Reference: 2-Bromo-5-fluorophenol(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Bromo-5-fluorophenol(147460-41-1)
• EPA Substance Registry System: 2-Bromo-5-fluorophenol(147460-41-1)

Safety Data

• Hazard Codes: Xi,Xn
• Statements: 36/37/38-20/22
• Safety Statements: 26-36-37/39
• RIDADR: UN 3334
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 147460-41-1(Hazardous Substances Data)

Usage

Chemical Properties

Colorless liquid

Uses

2-Bromo-5-fluorophenol may be used for the preparation of reaction intermediates required for the synthesis of polycyclic 5-HT3 and 5-HT4 antagonists. It may be used for the the nucleophilic substitution of the 2,2′,4,4′-tetrabromodiphenyl iodonium chloride (iodyl salt).

General Description

2-Bromo-5-fluorophenol an aryl fluorinated building block.

InChI:InChI=1/C7H3F13O4/c8-2(9,1-21)22-3(10,11)4(12,13)23-5(14,15)6(16,17)24-7(18,19)20/h21H,1H2

Upstream product

• 450-88-4 1-bromo-4-fluoro-2-methoxybenzene 
• 348-57-2 2,4-difluorobromobenzene 

Downstream Products

• 202857-88-3 2-Benzyloxy-1-bromo-4-fluoro-benzene 
• 72216-35-4 3-fluorophenyl phenylmethyl ether 
• 1073319-44-4 1-bromo-2-(3-chloropropoxy)-4-fluorobenzene 
• 1073319-14-8 1-bromo-2-(4-bromobutoxy)-4-fluorobenzene 
• 1073319-31-9 {1-[(2-bromo-5-fluorophenoxy)methyl]cyclopropyl}methanol 
• 1073318-98-5 2-(2-bromo-5-fluorophenoxy)ethanol 
• 1073319-49-9 tert-butyl [3-(2-bromo-5-fluorophenoxy)propyl]carbamate 
• 1073319-12-6 3-(2-bromo-5-fluorophenoxy)propan-1-ol 
• 1073319-95-5 C₁₄H₁₃BrFNO₅ 
• 1073319-55-7 tert-butyl (5-{5-[4-(2-bromo-5-fluorophenoxy)butyl]-1,3,4-thiadiazol-2-yl}-2H-tetrazol-2-yl)acetate 
• 1073319-21-7 ethyl (5-{3-[3-(2-bromo-5-fluorophenoxy)propoxy]isoxazol-5-yl}-2H-tetrazol-2-yl)acetate 
• 1009094-06-7 3-bromo-6-chloro-2-hydroxybenzaldehyde 
• 1020658-16-5 ethyl 5-{6-[4-(2-bromo-5-fluorophenoxy)piperidin-1-yl]pyridazin-3-yl}nicotinate 
• 1006878-92-7 tert-butyl 4-(2-bromo-5-fluorophenoxy)piperidine-1-carboxylate 

Relevant articles and documents

Identification of 4-(4-nitro-2-phenethoxyphenyl)pyridine as a promising new lead for discovering inhibitors of both human and rat 11β-Hydroxylase

The inhibition of 11β-hydroxylase is a promising strategy for the treatment of Cushing's syndrome, in particular for the recurrent and subclinical cases. To achieve proof of concept in rats, efforts were paid to identify novel lead compounds inhibiting both human and rat CYP11B1. Modifications on a potent promiscuous inhibitor of hCYP11B1, hCYP11B2 and hCYP19 (compound IV) that exhibited moderate rCYP11B1 inhibition led to compound 8 as a new promising lead compound. Significant improvements compared to starting point IV were achieved regarding inhibitory potency against both human and rat CYP11B1 (IC50 values of 2 and 163 nM, respectively) as well as selectivity over hCYP19 (IC50 Combining double low line 1900 nM). Accordingly, compound 8 was around 7-and 28-fold more potent than metyrapone regarding the inhibition of human and rat CYP11B1 and exhibited a comparable selectivity over hCYP11B2 (SF of 3.5 vs 4.9). With further optimizations on this new lead compound 8, drug candidates with satisfying profiles are expected to be discovered.